Board of Directors

Erik Nerpin

Chairman

Born in 1961. Lawyer. Self-employed with Advokatfirman Nerpin AB. Independent of the Company and its principal owners. Board member since 2012. Chairman of Kancera AB and Blasieholmen Investment Group AB and Board member in among others Effnetplattformen AB.

Holdings in Diamyd Medical as of August 31, 2019: 41 065 B-shares.

Anders Essen-Möller

Board Member

Born in 1941. M.Sc. Founder of and CEO during 1996-2007 of Diamyd Medical and Chairman 2007 –2015. Independent of the Company, principal owner. Founder of Synectics Medical AB, sold to Medtronic, Inc. in 1996. Chairman of NextCell Pharma AB.

Holdings in Diamyd Medical as of August 31, 2019: 2 556 223 A-shares and 7 333 040 B-shares. Essen-Möller also holds 1 863 333 B-shares via an endowment insurance.

Maria-Teresa Essen-Möller

Board Member

Born in 1970. M.Sc. in Business Administration. CEO of Health Solutions AB. Independent to the Company, not independent to its principal owners. Previous experience include Digital Marketing Manager at Sanofi and Account Director at Creuna. Board member since 2009.

Holdings in Diamyd Medical as of August 31, 2019: 63 998 B-shares.

Torbjörn Bäckström

Board Member

Born in 1948. MD, PhD. CEO of Umecrine AB. Independent of the Company and its principal owners. Board member since April 2017. Head of Neurosteroid Research Centre in Umeå and Senior Professor in the Department of Clinical Science, Obstetrics and Gynecology at Umeå University.

Holdings in Diamyd Medical as of August 31, 2019: -

Mark Atkinson

Board Member

Born in 1961. PhD. Professor of Diabetes Research, Department of Pathology, Immunology and Laboratory Medicine, University of Florida, USA. American Diabetes Association Eminent Scholar for Diabetes Research. Director, UF Diabetes Institute, University of Florida. Independent of the Company and its principal owners. Board member since November 2018.

Holdings in Diamyd Medical as of August 31, 2019:-

Management

Ulf Hannelius

CEO

Born in 1975. PhD in Molecular Biology from Karolinska Institutet in Stockholm and Executive MBA from Stockholm School of Economics. Prior experience from business development in the biotech and medtech industries as well as from academic research in the fields of genetics and molecular biology. Joined Diamyd Medical in 2015, CEO since 2016.

Holdings in Diamyd Medical as of August 31, 2019: 136 666 B shares.

Martina Widman

Director Clinical Development

Born in 1981. M.Sc. in Mechanical Engineering from the Royal Institute of Technology in Stockholm, with a specialization in Biomedical Engineering. Prior experience of clinical operation from the pharmaceutical industry. Joined Diamyd Medical in 2008.
Holdings in Diamyd Medical as of August 31, 2019: 20 000 B shares.

Anna Styrud

Chief Financial Officer

Born in 1961. B.Sc. in Business Administration from Uppsala University. Prior experience include Treasurer of Vasakronan AB and various positions in finance and control within real estate and engineering industry. Joined Diamyd Medical in 2010.

Holdings in Diamyd Medical as of August 31, 2019: 100 000 B-shares.

Anton Lindqvist

Chief Scientific Officer

Born in 1980. M.Sc in Molecular Biotechnology Engineering from Uppsala University. Research experience from University of Pittsburgh, Uppsala University, the Royal Institute of Technology and Karolinska Institutet. Prior experience in managing technical development at several bio-tech companies. Joined Diamyd Medical in 2013.

Holdings in Diamyd Medical as of August 31, 2019: -



Order GAD for preclinical research

GAD PRODUCTS